新型抗人胃肠癌单抗CMU15的研制及应用研究

PREPARATION OF MONOCLONAL ANTIEODY CMU15 REACTIVE WITH GASTROINTESTINAL CANCER AND ITS APPLICATION

用新鲜高分化大肠腺癌组织提取的亚细胞膜相成分为免疫原,采用淋巴细胞杂交瘤技术,经ABC免疫组化和亚细胞膜结合ELISA法进行筛选,研制出一种稳定的分泌IgG_1型的鼠单克隆抗体,命名为CMU15的杂交瘤。经免疫组化研究证实,该单抗与胃肠癌具有高选择性反应,阳性率分别为75.6％和31％,且与管状腺癌的分化程度有关,亦与淋巴结转移癌有较好的反应。正常组织仅见少数细胞有反应。同时检测76例胃癌前病变胃粘膜不典型增生其抗原表达与细胞异型增生相关,表明该单抗有益于监测癌变潜能。

The subcellmembranes from fresh tissues of colorectal well-differentiated carcinoma were used to immunize Balb/c mice, of which spleenecytes weie fused with SP 2/0 myeloma cells. The monclonal antibody (McAb) against gastrointestinal cancer secreted by hybridoma was screened by ABC-immunohistochemical and ELISA method and established, named CMU15 (IgG1). The distribution of the antigen defined by McAb CMU15 in GI cancer showed that (1) positive ratio as 75.6% and 80% resrectively; (2) highly expressed in well-differentiated carcinoma (P<0.0009); and (3) in normal tissues, only expressed in absorbent cells of intestinal metaplasia and neck cell of normal stomach. The expression of antigen defined by McAb CMU15 in 76 cases of gastric dysplasia showed that the positive ratio as 50% and highly expressed in moderate and severe dysplasia; much more interestings were carcinogenesis ratio in highly expressed group was 13.6% (5/38) but negative group only 5.26% (2/38)which suggested that in will be beneficial for evaluating potential malignance of gastric dysplasia.